Argent Biopharma Ltd (RGT) - Total Assets

Latest as of June 2025: AU$2.47 Million AUD ≈ $1.75 Million USD

Based on the latest financial reports, Argent Biopharma Ltd (RGT) holds total assets worth AU$2.47 Million AUD (≈ $1.75 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Argent Biopharma Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Argent Biopharma Ltd - Total Assets Trend (2006–2025)

This chart illustrates how Argent Biopharma Ltd's total assets have evolved over time, based on quarterly financial data. Explore RGT long-term investment intensity to see how much of total assets are deployed in long-term investments.

Argent Biopharma Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Argent Biopharma Ltd's total assets of AU$2.47 Million consist of 82.3% current assets and 17.8% non-current assets.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$0.00	41.5%
Accounts Receivable	AU$375.65K	15.2%
Inventory	AU$132.67K	5.4%
Property, Plant & Equipment	AU$0.00	0.0%
Intangible Assets	AU$0.00	0.0%
Goodwill	AU$0.00	0.0%

Asset Composition Trend (2006–2025)

This chart illustrates how Argent Biopharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Argent Biopharma Ltd worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Argent Biopharma Ltd's current assets represent 82.3% of total assets in 2025, an increase from 55.1% in 2006.
Cash Position: Cash and equivalents constituted 41.5% of total assets in 2025, down from 51.3% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2006.
Asset Diversification: The largest asset category is accounts receivable at 15.2% of total assets.

Argent Biopharma Ltd Competitors by Total Assets

Key competitors of Argent Biopharma Ltd based on total assets are shown below.

Company	Country	Total Assets
GALDERMA GROUP AG NYSE:GALDY	USA	$13.39 Billion
Changchun High & New Technology Industries Group Inc SHE:000661	China	CN¥30.77 Billion
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	China	CN¥17.84 Billion
Tianjin Zhongxin Pharmaceutical Group Corp Ltd SHG:600329	China	CN¥11.59 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	China	CN¥5.17 Billion
Dermapharm Holding SE XETRA:DMP	Germany	€2.27 Billion
China Animal Husbandry Industry Co Ltd SHG:600195	China	CN¥9.32 Billion
Daewoong Pharma KO:069620	Korea	₩2.26 Trillion

Argent Biopharma Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.19	0.23	1.09
Quick Ratio	0.18	0.15	0.95
Cash Ratio	0.00	0.00	0.00
Working Capital	AU$-8.80 Million	AU$-9.44 Million	AU$261.55K

Argent Biopharma Ltd - Advanced Valuation Insights

This section examines the relationship between Argent Biopharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	9.85
Latest Market Cap to Assets Ratio	1.18
Asset Growth Rate (YoY)	-77.1%
Total Assets	AU$2.47 Million
Market Capitalization	$2.91 Million USD

Valuation Analysis

Above Book Valuation: The market values Argent Biopharma Ltd's assets above their book value (1.18x), reflecting positive investor sentiment about the company's future prospects.

Significant Asset Reduction: Argent Biopharma Ltd's assets decreased by 77.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Argent Biopharma Ltd (2006–2025)

The table below shows the annual total assets of Argent Biopharma Ltd from 2006 to 2025.

Year	Total Assets	Change
2025-06-30	AU$2.47 Million ≈ $1.75 Million	-77.12%
2024-06-30	AU$10.79 Million ≈ $7.63 Million	+8.05%
2023-06-30	AU$9.98 Million ≈ $7.06 Million	-46.20%
2022-06-30	AU$18.56 Million ≈ $13.13 Million	-23.43%
2021-06-30	AU$24.24 Million ≈ $17.15 Million	+205.66%
2020-06-30	AU$7.93 Million ≈ $5.61 Million	-38.99%
2019-06-30	AU$13.00 Million ≈ $9.20 Million	-35.00%
2018-06-30	AU$19.99 Million ≈ $14.15 Million	-3.97%
2017-06-30	AU$20.82 Million ≈ $14.73 Million	+27.25%
2016-06-30	AU$16.36 Million ≈ $11.58 Million	+549.08%
2015-06-30	AU$2.52 Million ≈ $1.78 Million	-49.37%
2014-06-30	AU$4.98 Million ≈ $3.52 Million	-42.80%
2013-06-30	AU$8.70 Million ≈ $6.16 Million	+777.08%
2012-06-30	AU$992.36K ≈ $702.16K	+31.96%
2012-04-30	AU$752.00K ≈ $532.09K	-31.25%
2011-06-30	AU$1.09 Million ≈ $773.95K	-92.26%
2010-06-30	AU$14.13 Million ≈ $10.00 Million	-13.93%
2009-06-30	AU$16.42 Million ≈ $11.62 Million	+521.79%
2008-06-30	AU$2.64 Million ≈ $1.87 Million	-44.89%
2007-06-30	AU$4.79 Million ≈ $3.39 Million	-10.78%
2006-06-30	AU$5.37 Million ≈ $3.80 Million	--

About Argent Biopharma Ltd

AU:RGT Australia Drug Manufacturers - Specialty & Generic

Market Cap

$2.91 Million

AU$4.11 Million AUD

Market Cap Rank

#29512 Global

#1702 in Australia

Share Price

AU$0.04

Change (1 day)

+2.78%

52-Week Range

AU$0.03 - AU$0.15

All Time High

AU$125.00